Tiffany Lucas PhD U.S. FDA
Tiffany Lucas PhD U.S. FDA Gene Therapy CMC Reviewer, OTP, CBER
Dr. Tiffany Lucas joined FDA as a Gene Therapy Reviewer in 2018. She works on all lifecycle stages with gene therapy products, including commercial, BLA, IND, and preIND phases. Her interests include ex vivo modified cellular gene therapy products, lentiviral vector engineering, and rare disease. Prior to joining FDA, Dr. Lucas was an investment analyst for a biotech group focused on each stage biotechnology development and she also worked in technology evaluation, IP, and licensing. She completed postdoctoral studies at Washington University-St. Louis Medical School studying virus-immune interactions and earned her PhD in Microbiology at University of Missouri for her research on retroviral vector engineering.